Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


RESTORE-Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain: study protocol for a randomised controlled trial.

Kent P, O'Sullivan P, Smith A Dr, Haines T, Campbell A, McGregor AH, Hartvigsen J, O'Sullivan K, Vickery A, Caneiro JP, Sch├╝tze R, Laird RA, Attwell S, Hancock M.

BMJ Open. 2019 Aug 18;9(8):e031133. doi: 10.1136/bmjopen-2019-031133.


RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease.

Jahagirdar R, Attwell S, Marusic S, Bendele A, Shenoy N, McLure KG, Gilham D, Norek K, Hansen HC, Yu R, Tobin J, Wagner GS, Young PR, Wong NCW, Kulikowski E.

Mol Pharmacol. 2017 Dec;92(6):694-706. doi: 10.1124/mol.117.110379. Epub 2017 Sep 29.


A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice.

Jahagirdar R, Zhang H, Azhar S, Tobin J, Attwell S, Yu R, Wu J, McLure KG, Hansen HC, Wagner GS, Young PR, Srivastava RA, Wong NC, Johansson J.

Atherosclerosis. 2014 Sep;236(1):91-100. doi: 10.1016/j.atherosclerosis.2014.06.008. Epub 2014 Jun 28.


RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.

McLure KG, Gesner EM, Tsujikawa L, Kharenko OA, Attwell S, Campeau E, Wasiak S, Stein A, White A, Fontano E, Suto RK, Wong NC, Wagner GS, Hansen HC, Young PR.

PLoS One. 2013 Dec 31;8(12):e83190. doi: 10.1371/journal.pone.0083190. eCollection 2013.


Ephrin A5 expression promotes invasion and transformation of murine fibroblasts.

Campbell TN, Attwell S, Arcellana-Panlilio M, Robbins SM.

Biochem Biophys Res Commun. 2006 Nov 24;350(3):623-8. Epub 2006 Sep 26.


Integrin-linked kinase activity regulates Rac- and Cdc42-mediated actin cytoskeleton reorganization via alpha-PIX.

Filipenko NR, Attwell S, Roskelley C, Dedhar S.

Oncogene. 2005 Sep 1;24(38):5837-49.


Integration of cell attachment, cytoskeletal localization, and signaling by integrin-linked kinase (ILK), CH-ILKBP, and the tumor suppressor PTEN.

Attwell S, Mills J, Troussard A, Wu C, Dedhar S.

Mol Biol Cell. 2003 Dec;14(12):4813-25. Epub 2003 Sep 5.


Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343.

Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D, Yan J, Sanghera J, Walsh MP, Dedhar S.

J Biol Chem. 2001 Jul 20;276(29):27462-9. Epub 2001 Apr 19.


The integrin-linked kinase (ILK) suppresses anoikis.

Attwell S, Roskelley C, Dedhar S.

Oncogene. 2000 Aug 3;19(33):3811-5.


Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells.

Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J, Dedhar S.

Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3207-12.

Supplemental Content

Loading ...
Support Center